INKT

Mink Therapeutics Inc

NASDAQ: INKT · HEALTHCARE · BIOTECHNOLOGY

$12.00

-1.07% today

Updated 2026-09-11

Market cap

$57.82M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.47

Dividend yield

—

52W range

$8 – $17

Volume

0.0M

Market cap

$57.82M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.47

Dividend yield

—

52W range

$8 – $17

Volume

0.0M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

3.8

Quality

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

-18.2

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →251 stocks currently score above 75

Price targets

Analyst target

$39.00

+225.00%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

Stock snapshot

Strengths

Insufficient data

Risks

- Piotroski 3/9 — weak financial health

- Altman Z -18.23 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-2.08B

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$2.70B	$0.00	$0.00	$0.00	$0.00
Net income	$-27.99M	$-22.46M	$-10.78M	$-12.49M	$-3.13M
EPS	—	—	—	—	$-2.47
Free cash flow	$-19.12M	$-15.84M	$-9.56M	$-5.93M	$-2.08B
Profit margin	-1.03%	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
INKT	$57.82M	16	4.3	3.0	5.0	3.8	—	Avoid
LLY	$994.92B	76	9.3	10.0	5.0	6.0	—	Strong Buy
JNJ	$640.02B	59	4.7	8.5	2.7	6.0	-88.93%	Buy
ABBV	$454.36B	73	6.7	8.5	4.0	5.0	-69.36%	Strong Buy
MRK	$355.10B	36	4.0	4.5	2.0	5.0	-73.74%	Hold
UNH	$340.27B	62	7.3	5.5	4.7	6.0	-16.10%	Buy

Smart narrative

Mink Therapeutics Inc trades at $12.00. Our Smart Value Score of 16/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -18.23, it sits in the distress.

Frequently asked questions

What is Mink Therapeutics Inc's stock price?

Mink Therapeutics Inc (INKT) trades at $12.00.

Is Mink Therapeutics Inc overvalued?

Mink Therapeutics Inc carries a Smart Value Score of 16/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Mink Therapeutics Inc (INKT)?

The 12-month analyst consensus target is $39.00, about 225.0% above the current $12.00. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Mink Therapeutics Inc's Altman Z-Score is -18.23, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-1,239.00%

Beta0.48

50D MA$11.20

200D MA$11.38

Shares out0.01B

Float0.00B

Short ratio—

Avg volume0.0M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

INKT vs LLY →INKT vs JNJ →INKT vs ABBV →Stock screener →